ATRC
12.2.2024 15:12:30 CET | Business Wire | Press release
In a landmark announcement on Day 1 of the World Governments Summit (WGS) 2024, Abu Dhabi’s Advanced Technology Research Council (ATRC) unveiled a pioneering initiative aimed at facilitating global access to cutting-edge technology solutions. The newly launched ‘ATRC Global Tech R&D Platform’ serves as a channel for countries worldwide to tap into the UAE's technological expertise to address their unique challenges.
As the driving force behind Abu Dhabi and the wider UAE's advanced research and development (R&D) ecosystem, this initiative underscores ATRC's commitment to fostering inclusive growth and global prosperity. In an era of rapid technological transformation, the platform seeks to bridge technology gaps experienced by nations worldwide by offering tailored solutions to their pressing needs.
To initiate applications through the platform, ATRC is allocating US$200 million in funding to accelerate innovation, particularly for emerging and developing nations. By committing to absorb resource and research costs, the funding facilitates the development of sophisticated technology solutions, empowering these nations to keep pace with the latest advancements.
The ATRC Global Tech R&D Platform invites applications from governments, organizations, and eligible stakeholders all over the world, prioritizing collaboration, and inclusivity. Through a rigorous evaluation process, initiatives aligned with the platform's mission will receive support in six priority sectors: Aerospace and Space; Food and Agriculture; Healthcare; Safety and Security; Sustainability, Environment, and Energy; and Transport.
H.E. Faisal Al Bannai, Secretary General of ATRC, underscores the profound global impact of the initiative, stating: "Our commitment is to empower every nation with the means to thrive in this technology-driven world. ATRC stands ready to partner with countries worldwide, leveraging our expertise in technology to address their challenges and drive collective progress in the AI-driven era."
Over the span of almost four years, ATRC has developed a robust R&D ecosystem, with over 850 researchers from more than 70 countries. It has built an entire ecosystem that systematically supports every critical stage of a technology’s development journey. Its entity ASPIRE crowdsources global talent through grand challenges and global competitions and identifies technology gaps with its clients. The Technology Innovation Institute (TII) is focused on applied research with intentional outcomes and houses its leading researchers and scientists, while VentureOne commercializes its solutions, taking R&D products and services from lab to market.
ATRC offers a spectrum of capabilities spanning quantum and AI, autonomous robotics, and cryptography, as well as advanced materials, propulsion, and space – guiding technology needs from ideation to innovation.
From identifying an entity’s tech pain point to developing bespoke R&D solutions, ATRC orchestrates the complete lifecycle of technology advancement for companies and countries that need support. Situated at the global crossroads, it extends its reach to entities worldwide, facilitating innovation on a truly global scale.
Al Bannai is set to address a plenary session at the World Governments Summit, highlighting his views on AI’s evolution and emerging opportunities.
Dr. Ray O. Johnson, CEO of ATRC’s global applied research arm, TII, expressed optimism about the fund's potential to catalyze innovation, and said: "Through this platform, we will help identify untapped innovation around the world, unleashing the power of transformative technologies, and sparking economic growth."
ATRC is calling on nations to collaborate and contribute to the global technological landscape. For further details on the ATRC Tech R&D Fund, applicants can contact the Council via ASPIRE, at aspireuae.ae.
“We’re here to identify technology gaps and facilitate sophisticated solutions that countries may need to explore for a resilient future”, said Stephane Timpano, CEO of ASPIRE.
In a similar stance to support the wider adoption of advanced technologies, last year, the Technology Innovation Institute (TII) was among the first to open-source its world ranking large language model, Falcon 40B under the Apache 2.0 license – royalty-free.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212472252/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science21.9.2026 13:02:00 CEST | Press release
BioEridan, a Serbian biotechnology company backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a documentary charting its journey from an early scientific project in Belgrade to an emerging biotechnology venture focused on longevity research BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/ BioEridan Documentary Premiere BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026. The roundtable brought together prominent representatives fr
LabVantage Named a Visionary Leader in Life Sciences and Industrial LIMS by Frost & Sullivan21.9.2026 10:30:00 CEST | Press release
— Dual recognition in 2026 Frost Radar™ reports marks a fourth consecutive year of Frost Radar leadership — — Frost & Sullivan cited LabVantage CORTEX™ (for life sciences) and LIMS deployments spanning food and beverage, oil and gas, forensics, and government laboratories (for other industrial applications) — LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage’s Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage’s fourth consecutive year of Frost Radar leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921487430/en/ The Frost Ra
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 09:15:00 CEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
